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Summary: Concentrations of neopterin, which is produced by human monocytes/macrophages when stimulated by
γ-interferon, were measured in urine specimens from 72 patients with lung cancer at diagnosis. Other routine
clinical and laboratory variables were concomitantly determined. Neither neopterin nor any other laboratory variable
studied showed a significant correlation with clinical indicators of the disease (morphologic type, tumour stage,
grading, lymph node status, presence of distant metastases). The cancer patients were followed up for up to 10
years, and the abilities of all variables to predict fatal outcome were assessed. In univariate survival analyses, all
clinical indicators except morphologic type (P = 0.86) were significant predictors of survival (P < 0.002), but of
all the laboratory variables studied, only neopterin was significantly predictive (P = 0.0013). By multivariate sur-
vival analysis, a combination of four variables was found to jointly predict survival: lymph node status (P = 0.003,
multivariate model), tumour stage (P = 0.0006), grading (P = 0.0047) and neopterin (P = 0.0047). The data suggest
that certain aspects of immune activation may have adverse consequences for the prognosis of patients with lung
cancer.
Introduction cells, the activities of the constitutive enzymes, 6-pyru-
voyl-tetrahydropterin 2f-reductase (EC 1.1.1.220) and
Neopterin is biosynthesized from guanosine triphosphate reductase LLU53)> which catalyse
(GTP). Tlie key enzyme of ptendme biosynthesis, GTP subsequent reactions of teridine biosynthesis, are much
cyclohydrolase I (EC 3.5.4.16), is constitutively present ^ ±^ ^ ^ ̂  ^Q ̂  ̂ ^ Qf ̂
in neural and hepatic tissues but a cytokme-mducible indudble QTp c' ^ j .g icularl hi h (1)
form of this enzyme exists in many other tissues (1). In
human monocytes/macrophages, γ-interferon is the most Neopterin has been widely used as a sensitive in vivo
potent inducer of the enzyme (2), while tumour necrosis indicator of the activation state of the cellular immune
factor-α and lipopolysaccharide potentiate the effects of system in a broad variety of diseases, all of which are
γ-interferon (3). Human monocytes/macrophages differ characterized by involvement of activation of T lympho-
from other human and particularly murine cells (includ- cytes and production of γ-interferon and hence, activa-
ing murine macrophages) in that they produce by far the tion of monocytes/macrophages (4—6). In a variety of
highest amounts of neopterin after induction, whereas malignant diseases, neopterin concentrations in serum
all other cells synthesize equal or higher amounts of and excretion in urine have been found to be signifi-
biopterin derivatives. This peculiarity of human mono- cantly higher than in healthy controls, and, more impor-
cytes/macrophages stems from the fact that in these tantly, to be an independent prognostic indicator; ele-
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vated neopterin at the time of diagnosis of malignant
disease invariably indicates significantly shorter survival
times (7).
Lung cancer presents an interesting challenge for a can-
didate predictor with an immunological basis. Therefore,
in a retrospective analysis of 72 patients with lung can-
cer, the ability of urinary neopterin measured at time of




The study was based on 72 patients with lung cancer who were
diagnosed at the Department of Surgery II of the University Hospi-
tal of Innsbruck in 1983 and 1984 and for whom complete data
records were available. All investigations reported here were per-
formed before initiation of any specific tumour therapy. There were
63 men and 9 women; ages at diagnosis ranged from 40 to 80 years
with a median age of 62.5 years and an interquartile range from
55 to 71 years. Squamous cell carcinoma was found in 32 patients,
16 had small cell lung cancer, 12 had adenocarcinoma, 9 had large
cell carcinoma, and 3 adenosquamous carcinoma. For statistical
analyses, the latter 3 patients were combined with those with ade-
nocarcinoma. Stage T! was found in 13 patients, T2 in 31 patients,
T3 in 20 patients, and T4 in 8 patients. Stages were pTNM+ cTNM
stages. Lymph node status N0 was seen in 29 patients, 14 had Nb
21 had N2> and 8 had N3. In 19 patients, the tumour was highly
differentiated, 22 patients had moderately differentiated, and 31
poorly differentiated tumour. In 16 patients, distant metastases
were present at diagnosis.
Patients were grouped according to their general performance
status into three groups: performance status was good for 34
patients, moderate for 25 patients, and poor for 13 patients.
Several objective and subjective criteria were used for this classi-
fication; all evaluations were made by the same experienced
physician. · r
In 33 patients, therapy consisted of surgery only. Radiation therapy
only was administered to 17 patients, and 10 patients were treated
by chemotherapy only. Seven patients received surgery and radia-
tion therapy; 3 were treated by surgery and chemotherapy; 1 by
chemotherapy and radiation therapy. One patient received surgery,
chemotherapy and radiation therapy. Due to the small number of
patients in several therapeutic subgroups, therapy was not included
in the multivariate analysis of survival.
None of the patients included suffered from accompanying infec-
tious diseases at the time of investigation.
Laboratory examinations
Neopterin concentrations in first morning urine specimens col-
lected at diagnosis were determined by an optimized and fully au-
tomated high performance liquid chromatography technique with-
out oxidative pretreatment. The procedure is described in detail
elsewhere (8). By this technique, urinary creatinine is simulta-
neously determined in the same Chromatographie run. In order to
compensate for physiologic variations of urine concentrations,
neopterin levels are related to these creatinine values and are ex-
pressed as μπιοί of neopterin per mol of creatinine. The native
fluorescence of neopterin at 353 run excitation wavelength and 438
nm emission wavelength is used for detection; creatinine is quanti-
tated from its UV absorption at 235 nm. The performance charac-
Tab. 1 Results of laboratory measurements on patients with lung cancer, and their dependence on
tumour stage1
Variable First Median Third Range
quartile value quartile
Stage T2 Stage T3 Stage T4
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1 Median values of laboratory variables are given.
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teristics of the method were reported earlier (8); briefly, the analyti-
cal sensitivity of the method at a peak : noise ratio of 5 : 1 for
neopterin is 72 nmol/1 of undiluted urine, or 120 fmol per injection.
The sensitivity for creatinine is 36 pmol per injection. The method
is linear up to 40 μηιοΐ/ΐ for neopterin, and 26 mmol/1 for creati-
nine. Within-run precision of neopterin per creatinine ratio determi-
nation ranges from 3.8% to 6.5%; and between-day precision, from
2.8 to 7.4%.
Leukocyte and thrombocyte count, haematocrit, haemoglobin con-
centration, serum protein concentration, serum urea concentration
and serum concentration of alkaline phosphatase, γ-glutamyl trans-
ferase and aspartate aminotransferase at diagnosis were determined
by routine techniques.
Statistical procedures
Correlations between continuously coded variables were assessed
by the non-parametric Spearman's rank correlation technique,
since the distributions of observed values were generally non-
Gaiisslan. Differences of distributions of laboratory variables
among patient groups differing by clinical variables (such as tu-
mour stage) were tested for significance by a non-parametric analy-
sis of variance (Kwskal-Wallis test). Univariate survival analyses
were performed using the product-limit model (9); differences be-
tween survival curves were assessed for significance by the gener-
alized Savage test (Mantel-Cox test statistic). Categorization of pa-
tients according to continuously coded laboratory variables was in-
variably based on the quartile points of the observed distributions
of the variables. Multivariate survival analysis was performed by
the proportional hazards technique (10), using forward stepping of
variables. For this analysis, laboratory variables were dichotomized
on the basis of quartiles of the observed distributions. All statistical
analyses were done using the BMDP software package (BMDP
Statistical Software, Cork, Ireland). Specifically, program modules
BMDP2D (for descriptive analysis), BMDP3S (for non-parametric
correlation analysis and analysis of variance), BMDP l L (for pro-
duct-limit calculations) and BMDP2L (for the proportional hazards
model) were employed.
Results
Table 1 reports results of laboratory measurements, to-
gether with median values of biochemical analytes in
different tumour stages. Notably, by the Kmskal-Wallis
test, the tumour stage showed no significant effect on
any of the variable, with the exception of serum urea
concentration (P = 0.065; borderline significance).
Similarly, the effects of other clinical variables such as
performance status, morphologic tumour cell type, grad-
ing, and presence of metastasis on the laboratory vari-
ables were studied, but no interesting or significant ef-
fects were detected. These results are therefore not in-
cluded.
In an analogous fashion, effects on laboratory variables
of other important characteristics of the disease (mor^
phology, grading, presence of distant metastases) were
assessed (details not shown). Neopterin in particular was
not influenced by performance status (P = 0.13) mor-
phologic tumour' type (P = 0.22), grading (P = 0.37),
tumour stage (P = 0.47), and presence of distant meta-
stases (P = 0.73). Only the grouping of the patients on
the basis of lymph node status had any effect with bor-
derline significance on neopterin (P = 0.079). By Spear-
man's rank correlation analysis, neopterin showed weak
correlations with haematocrit (rs = —0.338,
P = 0.0044), leukocytes (rs = 0.283, P = 0.017), alka-
line phosphatase (rs = 0.277, P = 0.020) and haemoglo-
bin level (rs = -0.275, P = 0.021).
Univariate analysis of survival
Table 2 shows product-limit estimates of cumulative sur-
vival probabilities for patients, grouped according to
clinical and laboratory variables. For these estimates,
laboratory variables were grouped according to quartile
points of their respective distributions (see tab. 1). Of
the clinical variables, all except morphologic type were
significant predictors of survival. Of the laboratory vari-
ables only neopterin showed significant predictive
power, alkaline phosphatase was of borderline signifi-
cance, while all other laboratory variables showed no
correlation at all with survival expectation. Figure 1
shows the computed cumulative survival expectations
for the patients, grouped by three clinical variables and
Tab. 2 Predictive significance of clinical and laboratory1 vari-












































































1 Laboratory variables were grouped according to the quartile
points of observed distributions (see also tab. 1); categorical vari-
ables were used without transformation. For the categories thus
defined, product-limit estimates of cumulative survival probabili-
ties were constructed.
2 Generalized Savage test (Mantel-Cox test) for differences be-
tween cumulative survival probabilities.
3 Morphology was examined in two ways: (I) four groups
(squamous cell carcinoma, adenocarcinoma including adeno-
squamous carcinoma, large cell carcinoma, small cell lung cancer);
(2) two groups (squamous cell carcinoma combined with adeno/
adenosquamous carcinoma, large cell carcinoma combined with
small cell lung cancer).
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Fig. 1 Product-limit estimates of cumulative survival probabilities.
Upper left panel: Patients were stratified by lymph node status
(squares, N0; triangles, NI; diamonds, N2; circles, N3).
Upper right panel: Patients were stratified by grading (squares,







Time of observation [months]
Lower left panel: patients were stratified by T stage (squares, ΊΊ;
triangles, T2; diamonds, T3; circles, T4).
Lower right panel: Patients were stratified by neopterin levels
(squares, <174; triangles, 175-239; diamonds, 240-324; circles,
>324 μηιοΐ/mol creatinine).
by neopterin concentrations in urine. Notably, no lung
cancer-related deaths occurred later than four years after
diagnosis. From the survival of the patients grouped by
neopterin quartile points, it is obvious that the main dif-
ference was noted between the first three, and the last
quartile.
ability approximately 30%) than those with neopterin
exceeding this limit (no patient surviving longer than
four years after diagnosis). Similar results demonstrat-
ing the independent predictive significance of
neopterin were seen in other subgroups of patients
(data not shown).
Multivariate analysis of survival
Table 3 shows results of computations using the propor-
tional hazards model. For these analyses, laboratory vari-
ables were dichotomized using as cutoff-values either
the first (haematocrit, haemoglobin, serum protein: for
these variables, declining values are generally associated
with deterioration of disease) or the third quartile point
of the observed distributions (all other variables, for
which increasing values are generally symptomatic for
deterioration of disease). Univariate analysis using the
proportional hazards model produced essentially the
same results as the product-limit approach. When a step-
wise regression was performed including all variables as
candidate predictors, four variables (lymph node status,
tumour stage, grading and neopterin) were found to
jointly predict survival.
Figure 2 demonstrates that in patients with lymph
node status N0 who according to figure 1 exhibited a
long-term survival probability of about 50%, those
with neopterin below 324 μπιοΐ/mol creatinine had a
dramatically better prognosis (long-term survival prob-
Discussion
Neopterin is strongly associated with the prognosis of
lung cancer; high concentrations of neopterin in urine
at the time of diagnosis are a sign for an unfavourable
survival expectation, and this predictive information is
seen irrespective of other prognostic factors. Thus,
neopterin as an indicator of activation of cell-mediated
immune mechanism differs from a selection of several
routine laboratory variables which carry practically no
predictive information. This major result of the present
study on lung cancer patients agrees with analogous
observations in other malignancies: neopterin was
found to be a significant and independent predictor in
carcinoma of the uterine cervix (11) or of the ovaries
(12), in prostatic carcinoma (13), in patients with hep-
atocellular carcinoma (14), in various haematological
neoplasms (15-17), and in colon carcinoma (18).
Our study suffers from the fact that measurements of
specific tumour markers were not available. Previous
studies, however, investigating the relative predictive
Eur J Clin Chem Clin Biochem 1995; 33 (No 11)
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1 Multivariate survival analysis by the proportional hazards tech- 2 Cut-off value for dichotomizing patients on the basis of labora-
nique. tory variables.
3 Only jointly significant variables are included.
value of concomitantly measured neopterin and tumour
markers invariably showed that tumour markers, as com-
pared with neopterin, generally show a stronger relation-
ship to tumour stage but not to prognosis. In particular,
in women with ovarian carcinoma at second-look lapa-
rotomy, CA-125 concentrations were more strongly
correlated than neopterin to the amount of malignant tis-
sue found by the surgical exploration. However,
neopterin was an independent predictor of further prog*
nosis while CA-125 failed to yield significant prognostic
information in a multivariate analysis (19). Similar re-
sults were found in multiple myeloma when neopterin
was compared with interleukin-6 (17). TTius, at present
it appears that in comparison with specific tumour mark-
ers, neopterin as a product of an activated cellular im-
mune system is less strongly correlated to the actual





Time of observation ImonthsJ
Fig. 2 Product-limit estimates for cumulative survival probabili-
ties for patients with lymph node status NO. Patients were dichoto-
mized by urinary neopterin levels below (squares) versus above
(triangles) the third quartile (324 μτηοΐ neopterin per mol creati-
nine).
superior in providing independent predictive informa-
tion. We believe that neopterin concentrations reflect im-
portant tumour-host interactions rather than the quantity
of tumour cells. On the other hand, these interactions
are not easily accessible by other variables. The lack
of a significant correlation between tumour stage and
neopterin in the present study seems to corroborate the
foregoing statement. Notwithstanding the predictive sig-
nificance of neopterin, the well-established indicators of
tumour mass and invasiveness were also found to be
significant prognostic factors in the present study, and
the combination of these with neopterin seems to pro-
vide superior information.
Performance status is an important prognostic factor in
lung cancer patients. In our study, performance status as
a single predictive factor showed the strongest signifi-
cance of all variables tested. However, in multivariate
step-up analyses of survival, performance status entered
the model as first variable but was removed later in the
stepwise process of variable selection, when other vari-
ables entered the model. This was seen regardless of
whether the mutually correlated variables, stage and
lymph node status, were used for computation, or
whether one of them was dropped before the analysis.
Therefore, we conclude that performance status, while
representing an excellent single predictor, is not an inde-
pendent prognostic indicator when other predictive vari-
ables are taken into consideration.
Our study was based on only 72 patients with lung can-
cer. Therefore, it is not surprising that the results are not
completely in accordance with those of large scale
studies. For example, one would expect different sur-
Eur J Clin Chem Clin Biochem 1995; 33 (No 11)
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vival probabilities between stage T2 and T3 patients, and
different survival probabilities between patients with dif-
ferent Histologie cell types. Our study is certainly too
small to confirm all details of large scale studies; on the
contrary, based on previous studies on patients with
other types of malignant disease, the main aim of our
investigation was the assessment of a possible predictive
significance of neopterin concentrations in urine of lung
cancer patients.
The consistent observation of raised neopterin pro-
duction and secretion in many tumour patients, as well
as the invariably found correlation between high
neopterin levels (and, hence, in vivo activation of cell-
mediated immune reactions) and poor prognosis in vari-
ous malignancies, awaits definitive explanation. The
data on neopterin levels in various tumour patients seem
consistent with the view that in these patients recogni-
tion of tumour cells by, and early activation mechanisms
of, the immune system are intact, but effector functions
are severely suppressed.
Recent observations might offer a novel route to a better
understanding of this apparently paradoxical situation:
neopterin enhances reactions mediated by free radicals
(20-22). In particular, neopterin strongly enhances lum-
inol-dependent chemiluminescence induced by hy-
drogen peroxide (in the presence of iron chelator com-
plexes) or by chloramine T, and also cytotoxicity of
chloramine T against bacterial cultures. On the other
hand, its reduced form, 7,8-dihydroneopterin which is
also secreted in excess by activated human monocytes/
macrophages, is a strong scavenger of free radicals (20—
24). Since activated macrophages gain their cytotoxic
potential by their production and secretion of activated
oxygen species (oxidative burst), it is tempting to specie
late that human macrophages fine-regulate their cyto-
toxic capacity by means of neopterin and 7,8-dihydro-
neopterin. At present, research on the interaction be-
tween neopterin, and pteridines in general, and free radi-
cals is in its infancy. It is, therefore, too early to draw
definitive conclusions. Nevertheless, free radicals have
been implicated in the most diverse biological phenom^
ena (25), and future studies on the possible relevance of
interactions between pteridines and free radicals would
seem highly promising.
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